TRIM21 expression is downregulated and correlated with shorter overall survival in patients with hepatocellular carcinoma (145) and diffuse large B cell lymphoma (19), while high expression of TRIM21 is correlated with poorer clinical outcomes in glioma (119), pancreatic cancer (110, 146), soft tissue sarcoma (147) and esophageal squamous cell carcinoma (148). Here, TRIM21 is linked to pancreatic neoplasm.